Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction

[1]  F. Casellas,et al.  Thiopurine methyl‐transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine‐treated inflammatory bowel disease patients , 2011, Alimentary pharmacology & therapeutics.

[2]  A. Tricco,et al.  Assessment of Thiopurine S-Methyltransferase Activity in Patients Prescribed Thiopurines: A Systematic Review , 2011, Annals of Internal Medicine.

[3]  J. Sanderson,et al.  A Biochemical Mechanism for the Role of Allopurinol in TPMT Inhibition , 2011 .

[4]  J. V. van Ginkel,et al.  Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8‐year intercept cohorts , 2010, Inflammatory bowel diseases.

[5]  J. Sanderson,et al.  Low‐dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease , 2010, Alimentary pharmacology & therapeutics.

[6]  A. Yeoh,et al.  TPMT*26 (208F-->L), a novel mutation detected in a Chinese. , 2009, British journal of clinical pharmacology.

[7]  J. Gisbert,et al.  Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review , 2008, The American Journal of Gastroenterology.

[8]  K. Papadakis,et al.  Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[9]  Michael V. Bland,et al.  Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity , 2008, Pharmacogenetics and genomics.

[10]  D. Hommes,et al.  Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  S. Hanauer,et al.  Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  S. Marsh,et al.  Ethnic differences in pharmacogenetically relevant genes. , 2006, Current drug targets.

[13]  J. Lewis,et al.  Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. , 2006, Gastroenterology.

[14]  J. Duley,et al.  Observations on the use of allopurinol in combination with azathioprine or mercaptopurine , 2005, Alimentary pharmacology & therapeutics.

[15]  S. Hanauer,et al.  Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine , 2005, Alimentary pharmacology & therapeutics.

[16]  Michel Eichelbaum,et al.  Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. , 2004, Pharmacogenetics.

[17]  P. Söderkvist,et al.  Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. , 2004, Pharmacogenetics.

[18]  C Hassan,et al.  Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease , 2002, Alimentary pharmacology & therapeutics.

[19]  T. Bayless,et al.  Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease , 2001, Gut.

[20]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[21]  D. Collier,et al.  The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. , 1999, Pharmacogenetics.

[22]  H. McLeod,et al.  Thiopurine methyltransferase alleles in British and Ghanaian populations. , 1999, Human molecular genetics.

[23]  M. Relling,et al.  Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. , 1999, Human molecular genetics.

[24]  H. Simmonds,et al.  Low-dose allopurinol plus azathioprine/ cyclosporin/prednisolone, a novel immunosuppressive regimen , 1993, The Lancet.

[25]  R. Rundles.  Effects of allopurinol on 6-mercaptopurine therapy in neoplastic diseases. , 1966, Annals of the rheumatic diseases.